Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Myriad Genetics, Inc. - Common Stock
(NQ:
MYGN
)
6.135
-0.005 (-0.08%)
Streaming Delayed Price
Updated: 3:58 PM EST, Jan 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Myriad Genetics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
2 Unpopular Stocks That Deserve a Second Chance and 1 That Underwhelm
October 17, 2025
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can...
Via
StockStory
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
October 14, 2025
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations
From
Myriad Genetics, Inc.
Via
GlobeNewswire
3 Cash-Burning Stocks with Open Questions
October 14, 2025
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to...
Via
StockStory
Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know
October 10, 2025
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Via
StockStory
Topics
Economy
Government
World Trade
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV
October 08, 2025
From
D S Simon
Via
GlobeNewswire
A Look Back at Therapeutics Stocks’ Q2 Earnings: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Pack
October 01, 2025
Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Myriad Genetics (NASDAQ:MYGN) and its peers.
Via
StockStory
Topics
Artificial Intelligence
3 Unprofitable Stocks That Fall Short
September 30, 2025
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Via
StockStory
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
September 23, 2025
From
Myriad Genetics, Inc.
Via
GlobeNewswire
3 Small-Cap Stocks That Concern Us
September 17, 2025
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...
Via
StockStory
Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way
September 16, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Biogen...
Via
StockStory
Topics
Artificial Intelligence
1 Momentum Stock for Long-Term Investors and 2 Facing Challenges
September 15, 2025
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro...
Via
StockStory
3 Russell 2000 Stocks with Open Questions
September 05, 2025
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the...
Via
StockStory
Topics
Regulatory Compliance
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
September 04, 2025
From
Myriad Genetics, Inc.
Via
GlobeNewswire
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
September 03, 2025
Results published in the Journal of Clinical Psychopharmacology
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
August 27, 2025
From
Myriad Genetics, Inc.
Via
GlobeNewswire
3 Stocks Under $10 We Approach with Caution
August 22, 2025
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be...
Via
StockStory
Opendoor, SmartRent, Myriad Genetics, Reddit, and Unity Stocks Trade Down, What You Need To Know
August 20, 2025
A number of stocks fell in the afternoon session after the major indices continued to pull back, with technology stocks accounting for most of the market's largest decliners. A key reason for this...
Via
StockStory
Topics
Artificial Intelligence
Economy
World Trade
ANGLE Announces Collaboration with Myriad Genetics
August 20, 2025
Via
ACCESS Newswire
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
August 18, 2025
From
Myriad Genetics, Inc.
Via
GlobeNewswire
3 Healthcare Stocks We’re Skeptical Of
August 18, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six...
Via
StockStory
Topics
Stocks
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
August 13, 2025
Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing
From
Myriad Genetics, Inc.
Via
GlobeNewswire
MYGN Q2 Deep Dive: Oncology Strategy Shift and Product Execution Shape Guidance
August 13, 2025
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $213.1 million. The company’s full-year...
Via
StockStory
Topics
Artificial Intelligence
What's going on in today's session
↗
August 06, 2025
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
Why Is Myriad Genetics (MYGN) Stock Soaring Today
August 06, 2025
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 36.4% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and...
Via
StockStory
Topics
Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
August 06, 2025
Via
Benzinga
Here are the top movers in Wednesday's session.
↗
August 06, 2025
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday
↗
August 06, 2025
Via
Benzinga
The market is filled with gapping stocks in Wednesday's session.
↗
August 06, 2025
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
Via
Chartmill
Discover the top movers in Wednesday's pre-market session.
↗
August 06, 2025
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
August 06, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
